Ofatumumab
Brand name: Kesimpta Pen
Rank #119 of 500 drugs by total cost
$144.6M
Total Cost
14,774
Total Claims
$144.6M
Total Cost
491
Prescribers
$9,788
Cost per Claim
502
Beneficiaries
15,569
30-Day Fills
$295K
Avg Cost/Provider
30
Avg Claims/Provider
About Ofatumumab
Ofatumumab (sold as Kesimpta Pen) was prescribed 14,774 times by 491 Medicare Part D providers in 2023, costing the program $144.6M. At $9,788 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 116 | Sofosbuvir/Velpatasvir (Epclusa) | $149.4M | 6,544 |
| 117 | Dolutegravir/Rilpivirine (Juluca) | $148.9M | 41,081 |
| 118 | Lisinopril (Lisinopril) | $145.8M | 15,744,768 |
| 119 | Ofatumumab (Kesimpta Pen) | $144.6M | 14,774 |
| 120 | Emtricitab/Rilpiviri/Tenof Ala (Odefsey) | $144.1M | 37,441 |
| 121 | Eltrombopag Olamine (Promacta) | $142.8M | 10,876 |
| 122 | Alpha-1-Proteinase Inhibitor (Prolastin C) | $137.9M | 12,352 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology